Lantern Pharma’s LP-184 shows promising results in treating rare pediatric cancer, Atypical Teratoid Rhabdoid Tumors (ATRT).
The stock of Lantern Pharma has experienced a decrease of about 4.27%, currently priced at approximately $3.00.
Kreis Leslie W., a 10 percent owner, sold 3,639 shares, with the company’s market capitalization standing at approximately $32.3 million.
Lantern Pharma Inc. (NASDAQ:LTRN) is a biotechnology company focused on developing precision oncology therapies. The company leverages artificial intelligence and machine learning to identify and develop drugs for cancer treatment. Lantern Pharma’s innovative approach aims to provide targeted therapies for patients with specific cancer types, including rare pediatric diseases. The company operates in a competitive landscape, with other biotech firms also exploring AI-driven drug development.
Lantern Pharma’s LP-184 has shown promising results in treating Atypical Teratoid Rhabdoid Tumors (ATRT), a rare pediatric cancer. This was highlighted at the SNO Pediatric Conference, reinforcing the drug’s rare pediatric disease designation. The positive in vivo activity of LP-184 supports its progression towards clinical trials, showcasing Lantern Pharma’s dedication to developing new treatments for rare pediatric conditions.
Despite the promising developments with LP-184, Lantern Pharma’s stock (LTRN) has seen a decrease of about 4.27%, with a current price of approximately $3.00. The stock has fluctuated between $2.97 and $3.07 during the day. Over the past year, LTRN has experienced a high of $6.40 and a low of $2.55, indicating significant volatility in its market performance.
On May 29, 2025, Kreis Leslie W., a 10 percent owner of Lantern Pharma, sold 3,639 shares of Common Stock at $3.03 each. Following this transaction, Kreis Leslie W. retains 207,422 shares. The company’s market capitalization stands at approximately $32.3 million, with a trading volume of 26,554 shares today. Despite the stock’s recent decline, Lantern Pharma’s advancements in pediatric cancer treatment remain a focal point for investors.
